Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above

NCT03300362 is registered in ClinicalTrials.gov with Barinthus Biotherapeutics as lead sponsor.

NCT NCT03300362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03300362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above
Lead sponsor
Barinthus Biotherapeutics
Phase
Phase 2
Overall status
Terminated
Start date
October 13, 2017
Completion date
October 31, 2018
Enrollment
862 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

influenza